Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
EKF Diagnostics Holdings PLC on Monday said it anticipates revenue and earnings gains for its full-year, as it noted flat interim revenue for the first half of 2025.
The Cardiff-headquartered medical diagnostics company said revenue in the six that ended June 30 was £25.2 million, flat with the year before and in line with management expectations.
Gross margins improved to 50% from 48%, said EKF Diagnostics, with adjusted earnings before interest, tax, depreciation and amortisation showing ‘continued growth’.
At constant currency, EKF Diagnostics said that revenue and adjusted Ebitda rose by 2% and 9% respectively.
It added that its five-year plan is continuing in line with management expectations, noting a strong revenue performance in the key growth areas of Hematology, up 8% on-year, and beta-HB, up 12%.
Back in March at its full-year results, EKF Diagnostics outlined a five-year strategic development plan to deliver revenue growth and improved profitability across all of its divisions.
Looking to the full-year, it said it remains on track to achieve revenue and adjusted Ebitda in line with market expectations of £56.3 million and £12.3 million respectively. These are up 12% and 9.7% from £50.2 million and £11.3 million in 2024.
The company is set to report its half-year numbers on September 16.
Shares in EKF Diagnostics edged 3.4% higher to 27.40 pence on Monday afternoon in London.
Copyright 2025 Alliance News Ltd. All Rights Reserved.